Pain Research Forum Highlights AnaBios Human DRG Neurons Presentation at Pain and Migraine Therapeutics Summit
The Pain Research Forum highlighted AnaBios CEO Dr. Andre Ghetti's recent presentation at the 11th Annual Pain and Migraine Therapeutics Summit in San Diego, California. Dr. Ghetti discussed the importance of utilizing human DRG neurons early in the drug discovery process to accurately predict human responses to molecular compounds.From the article:The human DRG neurons, Ghetti said, have great predictive value for development of pharmaceutical agents. For example, one compound—an unnamed sodium channel blocker—showed promise in rodents, halting firing of action potentials in DRG neurons and reversing hypersensitivity in vivo. But the compound had no effect on human DRG neurons, even [...]
AnaBios to Present Adult Human Primary Cardiomyocyte Research on Safety Pharmacology Society Webinar
AnaBios Scientific Director Najah Abi-Gerges, PhD, will present "Adult Human Primary Cardiomyocyotes: An Integrative Translational Model for Cardiotoxicity Assessment" on Thursday, November 2, from 11am-12pm EDT. Drug-induced irregular heart beat (pro arrhythmia) and/or changes in contractility (inotropic liability) can limit the utility of potential novel therapeutics. Since abnormal ventricular repolarization can cause not only electrical disorders, but also affect the heart’s contractile function, the main motivation of this study was to develop a new model based on adult human primary cardiomyocytes to provide a preclinical tool for the simultaneous prediction of drug-induced inotropic and pro-arrhythmia risks. To facilitate the scalability [...]
A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk.
Thursday, March 16th from 8:30 am to 11:45 am: "A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk." Hall A of the Exhibit Hall (Dr. Najah Abi-Gerges). If you will be at the meeting in March, please contact Alisen James: email@example.com, to let us know. We forward to connecting with both colleagues and clients.
Adult Human Primary Cardiomyocytes: An Integrative Translational Model for Cardiotoxicity Assessment.
Tuesday, March 14th - 9:30 am to 12:45 pm: "Adult Human Primary Cardiomyocytes: An Integrative Translational Model for Cardiotoxicity Assessment." Hall A of the Exhibit Hall area (Dr. Najah Abi-Gerges)
AnaBios to attend the 2017 Society of Toxicology Annual Meeting and Exposition in Baltimore, MD, U.S.A.
Upcoming in March, AnaBios will be presenting and exhibiting at the 2017 Society of Toxicology Annual Meeting and Expo, taking place at the Baltimore Convention Center, March 13th – 16th. AnaBios’ exhibit/booth number is #519. Dr.’s Paul Miller and Najah Abi-Gerges will be in attendance to discuss the latest in research and service offerings. Poster presentations are as follows:
AnaBios CEO Andre Ghetti to speak at the 8th Japanese Safety Pharmacology Society Annual Meeting at the University of Tokyo in Tokyo, Japan,
AnaBios CEO Andre Ghetti has been invited to present at the 8th Japanese Safety Pharmacology Society Annual Meeting, taking place at the University of Tokyo, February 10th - 11th, 2017. Dr. Ghetti will speak on "Adult Human Ex-Vivo Cardiac Models for Preclinical Safety Assessment."
AnaBios invited to speak at prestigious Gordon Research Conference in Ventura, CA, February 6th – 10th, 2017. Dr. Najah Abi-Gerges, Scientific Director for AnaBios, has been accepted to speak at The Gordon Research Conference in February 2017, in Ventura, CA. Dr. Abi-Gerges will speak on " “Proarrhythmia Predictions Using Primary Human Cardiomyocytes." The Gordon Research Conference, founded in 1941, is a prestigious international scientific conference, dedicated to highlighting the latest in cutting-edge research in fields ranging from physics to neurobiology, and material science to medicine. The conference is limited to 200 attendees; all presenters must apply and be [...]
Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform
December 5, 2016: Program will Accelerate Purdue’s Nav1.7 Sodium Ion Channel Drug Candidates with AnaBios’ Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today a collaboration to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain. The goal of the collaboration is to accelerate Purdue's Nav1.7 sodium ion channel drug candidates utilizing AnaBios' Phase-X® discovery platform to develop treatments for chronic pain. Under the terms of the agreement, Purdue Pharma will license to AnaBios the rights to a suite of patents for Nav1.7 sodium ion channel blockers. AnaBios will employ its Phase-X® technology [...]
April 4 - 6, 2016: Purdue Pharma CEO discusses the alliance with AnaBios at BIO-Europe 2016 in Stockholm, Sweden. Purdue Pharma CEO, Mark Timney, discusses the company's strategy and the alliance with AnaBios, in an interview with Pharma Intelligence's Mike Ward. An excerpt of the interview is available by clicking on the video. Video: 2016 Purdue CEO discusses the Purdue-AnaBios alliance and plans for growth away from opioid market
AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic
September 28 - October 1, 2015: AnaBios presents at 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic. The findings of collaborative work between AnaBios, AbbVie, Novartis and Roche were presented at the 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic. The presentation summarizes the results obtained employing Phase-X® ex-vivo human-based model that uses ventricular trabeculae from donor hearts, combined with sharp-electrode continuous recordings of the membrane potential to provide a novel approach for assessing pro-arrhythmic risks. The use of adult human cardiac tissue removes the potential for discrepancies in pharmacological sensitivity due to cross-species [...]
Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment
September 22, 2015: Purdue Pharma and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment Project aims to Advance Nav1.7 Sodium Ion Channel Drug Candidates with Phase-X® Discovery Platform Purdue Pharma L.P. and AnaBios Corporation announced today the intent to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel compounds for the treatment of chronic pain. The joint research and development effort would leverage Purdue Pharma's intellectual property and lead compounds, combined with AnaBios' Phase-X® technology. Purdue Pharma has more than 10 years of research history in the sodium channel field that [...]